Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer

Inclusion Criteria: * Written informed consent (IC) obtained. * Histologically confirmed adenocarcinoma of prostate * Progressive metastatic disease * Ongoing androgen deprivation therapy with a luteinising hormone-releasing hormone (LHRH) analogue or antagonist or bilateral orchiectomy * Adequate bone marrow, hepatic and renal function * Able to swallow the ODM-201 whole as a capsule or tablet. Exclusion Criteria: * Previous chemotherapy for prostate cancer. * Known metastases in the brain. * History of other malignancy within the previous 5 years, except a basal cell carcinoma of skin. * Known gastrointestinal condition that can significantly affect the absorption of the study treatment.